Search

everythinglearnresearchcommunity

for

Search:↓

Research 10 of 74

1. No Increased Cardiovascular Hazard with Oral 5-Alpha-Reductase Inhibitors in Treatment of Androgenetic Alopecia: A TriNetX Retrospective Cohort Study Journal of the American Academy of Dermatology · 2026
2. Reduced Prostate Cancer Risk in Patients with Androgenetic Alopecia Using 5-Alpha Reductase Inhibitors: A TriNetX Real-World Cohort Study Mendeley Data · 2025
3. Low-dose oral minoxidil for androgenetic alopecia is not associated with blood pressure changes in patients also taking other antihypertensive medications: A multi-center cohort study using TriNetX Journal of the American Academy of Dermatology · 2025
4. 76976 Association of Depression with Finasteride Stratified by Dosage and Diagnosis: A Retrospective Cohort Study Using the TriNetX Database Journal of the American Academy of Dermatology · 2026
5. The Association Between 5α-Reductase Inhibitors and the Presence of Subsequent Dry Eye Disease in Androgenetic Alopecia: A TriNetX Database Study Cureus · 2025
6. No elevated risk for osteoporosis or osteopenia among women with androgenetic or frontal fribrosing alopecia treated with 5-alpha reductase inhibitors: A retrospective TriNetX cohort study Journal of the American Academy of Dermatology · 2026
7. Nonscarring Alopecia in Adults Treated With GLP ‐1s: A Propensity Score Matched TriNetX Cohort Study The Laryngoscope · 2026
8. 0414 Cumulative atopic disease burden is associated with increased risk of alopecia areata: A TriNetX cohort study Journal of Investigative Dermatology · 2026
9. Reduced Prostate Cancer Risk in Patients with Androgenetic Alopecia Using 5-Alpha Reductase Inhibitors: A TriNetX Real-World Cohort Study Journal of the American Academy of Dermatology · 2026
10. Reduced Prostate Cancer Risk in Patients with Androgenetic Alopecia Using 5-Alpha Reductase Inhibitors: A TriNetX Real-World Cohort Study Mendeley Data · 2026

Community

— no results